Table 2.

Comparison of immune responses to PCV10 versus PCV7 among toddlers

Study	Vesikari et al. [38]								Kim et al. [39]
Country (year)	Finland, France and Poland (2009)								Korea (2011)
Dosing schedule	1 dose (12–18 months)								1 dose (12–18 months)
Vaccine	PCV7				PCV10				PCV7				PCV10
Immunogenicity	OPA titer		ELISA(IgG, μg/mL)		OPA titer		ELISA(IgG, μg/mL)		OPA titer		ELISA(IgG, μg/mL)		OPA titer		ELISA(IgG, μg/mL)
	GMT	≥1:8 (%)	GMC	≥0.20 (%)	GMT	≥1:8 (%)	GMC	≥0.20 (%)	GMT	≥1:8 (%)	GMC	≥0.20 (%)	GMT	≥1:8 (%)	GMC	≥0.20 (%)
PCV7 serotypes
4	2,813	100	4.40	100	1,856	100	3.35	99.7	3,717	100	12.19	100	1,058	99.3	5.77	100
6B	3,460	98.7	3.53	97.7	981	96.6	1.94	96.5	3,827	97.8	7.09	100	547	94.7	2.78	97.5
9V	5,357	100	6.09	100	2,344	100	3.25	100	5,204	100	12.72	100	1,708	100	4.99	100
14	2,134	100	9.29	100	2,086	100	5.56	99.1	3,958	100	22.22	100	1,815	100	7.73	100
18C	969	100	5.21	100	810	99.7	5.01	100	1,723	100	14.53	100	608	100	13.14	100
19F	288	92.5	3.35	100	624	94.9	6.05	99.4	277	97.7	4.82	100	1,285	98.7	16.89	98.7
23F	13,901	98.8	6.67	98.9	2,830	99.7	2.38	97.4	29,919	97.7	14.81	98.0	2,703	99.3	3.75	98.7
Other serotypes
1	4	3.6	0.04	4.9	192	91.0	1.53	99.4	5	6.4	0.06	11.0	364	94.6	4.03	99.7
5	4	1.2	0.05	6.1	144	96.3	2.20	99.4	4	0.0	0.19	38.2	234	97.3	5.51	100
7F	25	31.1	0.04	7.1	330	99.7	3.50	100	1,038	93.5	0.06	13.7	5,468	100	5.39	99.7
Cross-reactive serotypes
6A	873	94.9	1.53	89.5	255	85.0	0.71	84.4	1,416	97.7	2.51	91.2	196	78.8	0.99	85.8
19A	11	27.6	0.47	76.5	29	48.8	0.85	83.8	16	38.6	0.32	59.8	65	69.2	1.54	84.9

OPA, opsonophagocytosis assay; GMC, geometric mean concentration; GMT, geometric mean titer (calculated from the reciprocal of the individual titers)